Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

14. Juni 2022 11:00 ET | Quelle: NeuroSigma, Inc.

NeuroSigma Announces That a Team Led by UCLA Researchers Receives NIH Grant to Conduct a Multicenter Trial of eTNS for Pediatric ADHD

Double-blind randomized controlled trial will enroll up to 225 children at UCLA and Seattle Children’s Hospital NeuroSigma will provide Monarch eTNS Systems and funding for long-term follow-up ...
07. April 2022 11:00 ET | Quelle: NeuroSigma, Inc.

NeuroSigma Announces King’s College London Team Receives MHRA Approval to Commence Largest Clinical Trial of eTNS for Pediatric ADHD to Date

Double-blind randomized controlled trial of eTNS for pediatric ADHD will enroll up to 150 participants at two sites in London and Southampton NeuroSigma’s Monarch eTNS System and electric patches to...
25. Januar 2022 22:30 ET | Quelle: NeuroSigma, Inc.

Ignis Therapeutics Licenses NeuroSigma eTNS Technology for ADHD in a Significant China Licensing Transaction

Ignis obtains rights to develop and commercialize NeuroSigma’s FDA-approved Monarch eTNS System in ChinaInitial launch of Generation 1.0 device followed by Generation 1.5 device, to deploy in mainland...
08. Dezember 2021 05:00 ET | Quelle: NeuroSigma, Inc.

NeuroSigma Announces a $5 Million Equity Investment by KT Corporation

Transaction follows the June 2021 announcement of a strategic digital health partnership between NeuroSigma and KTSignificant investment in NeuroSigma’s digital health and neuro-electronics platform ...